Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North AmericaTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLong-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equalHIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.New drugs for HIV therapy.Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenA comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 yearsAssociation of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenTreatment interruption in advanced failing patients.Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting.Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks.A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission.
P50
Q21521430-6B94FF55-6A5E-4892-A323-4E97E39538B2Q24656950-727D9754-4D68-4F01-B772-BDA89FDBF25AQ28256092-95319747-35EB-4A1D-8F70-4E941D4FDDE8Q30983924-3128BF0F-7CB6-4B77-A416-EF61779782BAQ33269695-CB345058-A39D-42FB-ABFF-93B41B3AF5C3Q34139859-FC94738F-A27D-4579-B3DB-B842593C43F8Q34351993-459EBAA0-39E6-44CA-9A27-0EBA55978631Q34487847-4F185187-5246-44E8-8A24-E7AA457B1F1FQ34546011-5B987356-6102-4FB8-82DB-2D4599A5508CQ34546056-D807084D-258B-4242-98F5-F9556FB976DFQ34554560-EB51DE8D-E66F-442E-9DEE-7CEA63AF8E93Q35108722-E8C1E6A9-18E5-4653-A0E6-E9D6B3AC7B92Q35758844-7E0AC836-BF0F-41A0-9B97-7A6AA3051A6CQ35827891-A9C7DA6C-D49B-4C7A-B202-FB26AFC0E23CQ35870814-ED587C10-06FB-4380-A9F6-D7281E0A9782Q36094901-C63FA6A2-3CDF-41DC-BCAE-50AFFE4EC802Q36702983-822A59CE-757B-42E1-AF46-D3EFD5CCA22EQ37447136-19F3341D-61A9-4400-BEF7-40F91DB0B2D3Q37475726-F7C88BDC-13C5-4E43-8F4B-930684809259Q38421615-FF7233D3-05DC-4226-91BF-573111DDEF48Q39730755-3019C211-2985-494F-B1B1-4B474E51799CQ40508320-70AAEF5E-B234-466A-A4E3-856AF741342DQ42996145-05FCE7E9-B1B9-41D1-B4C8-188296304227Q43658048-48A8589F-045A-4015-8AAD-1C48D326655AQ43671930-E3FC31F8-722D-41BD-9DF5-864771954135Q43846085-FD7F6AEB-A978-4956-A0BD-2B65202352BEQ44097506-6C0AA5EE-58E3-4522-A80C-8FD2F008F94EQ44470874-5AB1F58A-FB9A-42F7-953F-9BF7628F6326Q44533053-8380FCDF-5BD3-4F2E-9800-436B4E855457Q44635705-2C81A43D-D375-4714-8940-88C37D1C7DA6Q44695492-2CA44C2E-CABF-48D6-B0AB-2214178C349AQ44699308-D943858C-E331-4D87-A87E-F68A70FB69B4Q44967524-DF5A59F0-672A-4A2F-BAF1-28A63F4F746CQ44975155-9C33443B-69EF-4647-9207-27C0B873E6DCQ45272010-69460775-D877-46A0-87AD-F1C72E1AAC7EQ45422795-94407F93-CD3A-4D90-B200-C968DDFD060FQ45730639-AFF95357-D9CC-46F7-9CB2-00E679401032Q46127992-06208D8C-1C00-42B5-BFB7-A98CF83AAB2CQ46132439-3145E24B-91F6-4158-8E5B-AF6A7609A23DQ46229848-87D30B90-70CF-4FB0-8714-DCDD3B63C530
P50
description
Duits hoogleraar
@nl
German university teacher
@en
German university teacher
@en-ca
German university teacher
@en-gb
Saksamaa ülikooli õppejõud
@et
deutscher Infektiologe und HIV-Forscher
@de
profesor universitar german
@ro
profesor universitar gjerman
@sq
profesor universitario alemán
@es
profesor universitario alemán
@gl
name
Schlomo Staszewski
@ast
Schlomo Staszewski
@ca
Schlomo Staszewski
@da
Schlomo Staszewski
@de
Schlomo Staszewski
@en
Schlomo Staszewski
@es
Schlomo Staszewski
@fr
Schlomo Staszewski
@nds
Schlomo Staszewski
@nl
Schlomo Staszewski
@pt
type
label
Schlomo Staszewski
@ast
Schlomo Staszewski
@ca
Schlomo Staszewski
@da
Schlomo Staszewski
@de
Schlomo Staszewski
@en
Schlomo Staszewski
@es
Schlomo Staszewski
@fr
Schlomo Staszewski
@nds
Schlomo Staszewski
@nl
Schlomo Staszewski
@pt
prefLabel
Schlomo Staszewski
@ast
Schlomo Staszewski
@ca
Schlomo Staszewski
@da
Schlomo Staszewski
@de
Schlomo Staszewski
@en
Schlomo Staszewski
@es
Schlomo Staszewski
@fr
Schlomo Staszewski
@nds
Schlomo Staszewski
@nl
Schlomo Staszewski
@pt
P214
P227
P244
P106
P1412
P1559
Schlomo Staszewski
@de
P19
P21
P213
0000 0000 3959 0440
P214
P227
P244
nb99002323
P31
P569
1951-01-01T00:00:00Z
P735
P7859
lccn-nb99002323